弗雷明汉心脏研究无痴呆参与者中主动脉僵硬度和压力搏动性与全局β-淀粉样蛋白及区域tau负荷的关联
该横断面研究纳入弗雷明汉心脏研究第三代队列中257名无痴呆参与者,评估主动脉僵硬度和压力搏动性与脑内β-淀粉样蛋白斑块及区域tau负荷的关联。结果显示较高的中心脉压和正向波振幅与内嗅皮层及鼻周皮层tau负荷增加相关,而与全局β-淀粉样蛋白斑块及其他脑区tau无关;在≥60岁参与者中关联更明显。作者认为主动脉僵硬度可能是预防tau相关病理的潜在可干预靶点。
要点
- 较高的中心脉压(β per SD=0.17,95%CI 0.00-0.35,P=.045)和正向波振幅(β per SD=0.16,95%CI 0.00-0.31,P=.04)与内嗅皮层tau负荷增加相关。
- 较高的中心脉压(β per SD=0.19,95%CI 0.02-0.36,P=.03)和正向波振幅(β per SD=0.17,95%CI 0.01-0.32,P=.03)与鼻周皮层tau负荷增加相关。
- 主动脉僵硬度和压力搏动性指标与杏仁核、下颞叶、楔前叶tau负荷或全局β-淀粉样蛋白斑块无关联。
核心结论
- 在该横断面研究中,异常的中心血管血流动力学与特定脑区较高的tau负荷相关。
- 研究结果提示,主动脉僵硬度可能是一个可干预的独立靶点,用于预防tau相关病理。
研究设计与样本
- 横断面研究,样本来自弗雷明汉心脏研究第三代队列第3次检查(N=3171;2016-2019),其中3092人成功完成综合血流动力学评估。
- 在补充访视(2015-2021)中,270名无痴呆且代表血管风险谱的参与者接受了正电子发射断层扫描;排除13名协变量数据缺失者后,最终样本量为257名参与者。
主要发现
- 257名参与者的平均(SD)年龄为54(8)岁,其中女性126名(49%),所有参与者均为白人西欧裔。
- 在多变量模型中,较高的中心脉压(β per SD=0.17;95%CI 0.00-0.35;P=.045)和正向波振幅(β per SD=0.16;95%CI 0.00-0.31;P=.04)与较高的内嗅皮层tau负荷相关。
- 在类似模型中,较高的中心脉压(β per SD=0.19;95%CI 0.02-0.36;P=.03)和正向波振幅(β per SD=0.17;95%CI 0.01-0.32;P=.03)与较高的鼻周皮层tau负荷相关。
- 主动脉僵硬度和压力搏动性指标与杏仁核、下颞叶、楔前叶tau负荷或全局β-淀粉样蛋白斑块无关联。
- 内嗅皮层和鼻周皮层tau结局的关联在年龄较大(≥60岁)参与者中更明显;例如,在分层分析中,所有主动脉僵硬度和压力搏动性指标较高(β per SD=0.40-0.92;P=.001-.02)与年龄较大参与者较高的内嗅皮层tau负荷相关,而在年龄较轻参与者中无此关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Aortic stiffness is associated with clinical hallmarks of Alzheimer disease and related dementias and could be a modifiable target for disease prevention. OBJECTIVE: To assess associations of aortic stiffness and pressure pulsatility with global amyloid-β plaques and regional tau burden in the brain of middle-aged and older adults without dementia. DESIGN, SETTING, AND PARTICIPANTS: The sample for this cross-sectional study was drawn from the Framingham Heart Study Third Generation Cohort at examination 3 (N = 3171; 2016-2019), of whom 3092 successfully underwent comprehensive hemodynamic evaluations. In a supplemental visit (2015-2021), a subset of 270 participants without dementia who represented the spectrum of vascular risk also underwent positron emission tomography. Thirteen participants were excluded for missing covariate data. The final sample size was 257 participants. EXPOSURES: Three measures of aortic stiffness and pressure pulsatility (carotid-femoral pulse wave velocity, central pulse pressure [CPP], and forward wave amplitude [FWA]) were evaluated using arterial tonometry. MAIN OUTCOMES AND MEASURES: Global amyloid-β plaques and regional tau were assessed using 11C-Pittsburgh compound B and 18F-flortaucipir positron emission tomography tracers, respectively. RESULTS: The mean (SD) age of the 257 participants was 54 (8) years, and 126 were women (49%). All participants were White Western European race. In multivariable models, higher CPP (β per SD = 0.17; 95% CI, 0.00-0.35; P = .045) and FWA (β per SD = 0.16; 95% CI, 0.00-0.31; P = .04) were associated with greater entorhinal tau burden. In similar models, higher CPP (β per SD = 0.19; 95% CI, 0.02-0.36; P = .03) and FWA (β per SD = 0.17; 95% CI, 0.01-0.32; P = .03) were associated with greater rhinal tau burden. Aortic stiffness and pressure pulsatility measures were not associated with amygdala, inferior temporal, precuneus tau burden, or global amyloid-β plaques. Associations for entorhinal and rhinal tau outcomes were more prominent in older participants (≥60 years). For example, higher levels of all aortic stiffness and pressure pulsatility measures (β per SD = 0.40-0.92; P = .001-.02) were associated with higher entorhinal tau burden among older but not younger participants in stratified analyses. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, abnormal central vascular hemodynamics were associated with higher tau burden in specific brain regions. Findings suggest that aortic stiffness, which is potentially modifiable, may be a probable independent target for prevention of tau-related pathologies.
引用
- Cooper LL, O'Donnell A, Beiser AS, et al. Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-β and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia. JAMA Neurol. 2022. PMID: 35666520. doi:10.1001/jamaneurol.2022.1261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。